Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- GLPG
- Price
- 34.40
- Stock movement up
- +0.92 (2.75%)
- Company name
- Galapagos NV ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.27B
- Ent value
- 3.44B
- Price/Sales
- 7.90
- Price/Book
- 0.79
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 128.60
- PEG
- -
- EPS growth
- -14.79%
- 1 year return (CAGR)
- 44.36%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
GLPG does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.90 |
| Price to Book | 0.79 |
| EV to Sales | 12.00 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 65.90M |
| EPS (TTM) | -6.62 |
| FCF per share (TTM) | -4.36 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 286.92M |
| Gross profit (TTM) | 422.74M |
| Operating income (TTM) | -524.88M |
| Net income (TTM) | -435.95M |
| EPS (TTM) | -6.62 |
| EPS (1y forward) | 0.27 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 147.34% |
| Operating margin (TTM) | -182.94% |
| Profit margin (TTM) | -151.94% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 75.74M |
| Net receivables | 91.26M |
| Total current assets | 3.72B |
| Goodwill | 0.00 |
| Intangible assets | 8.72M |
| Property, plant and equipment | 0.00 |
| Total assets | 4.13B |
| Accounts payable | 118.24M |
| Short/Current long term debt | 8.81M |
| Total current liabilities | 430.71M |
| Total liabilities | 1.25B |
| Shareholder's equity | 2.88B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -269.36M |
| Capital expenditures (TTM) | 17.68M |
| Free cash flow (TTM) | -287.04M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -15.16% |
| Return on Assets | -10.56% |
| Return on Invested Capital | -15.15% |
| Cash Return on Invested Capital | -9.98% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 33.97 |
| Daily high | 34.55 |
| Daily low | 33.97 |
| Daily Volume | 122K |
| All-time high | 274.03 |
| 1y analyst estimate | 27.64 |
| Beta | -0.05 |
| EPS (TTM) | -6.62 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 24 Feb 2026 |
Downside potential
Loading...
Downside potential data
| GLPG | S&P500 | |
| Current price drop from All-time high | -87.45% | -0.89% |
| Highest price drop | -91.72% | -19.00% |
| Date of highest drop | 4 Feb 2025 | 8 Apr 2025 |
| Avg drop from high | -89.38% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.27B
Marketcap category
Mid-cap
Description
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Employees
704
Website
Investor relations
-
SEC filings
CEO
Onno van de Stolpe
Country
USA
City
Mechelen
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page